Abstract A169: Overcoming tumor-associated immune suppression and resistance to cancer immunotherapy using Hyal2-ADCC
Sergei Kusmartsev(University of Florida Health), Paul L. Crispen(University of Kentucky), Brianna Nguyen(University of Florida), William Donelan(University of Florida), Paul R. Dominguez‐Gutierrez(RTI Surgical (United States)), Meng‐Lun Hsieh(Southwestern Medical Center), Wayne Brisbane(University of California, Los Angeles), Shiwu Li(University of Florida), Padraic O’Malley(University of Florida)
Cited by 0
Related Papers
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
|The Lancet Oncology|2020|459
An overview of kidney stone imaging techniques
|Nature Reviews Urology|2016|389
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling
|European Urology|2022|169
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin–Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
|The Journal of Urology|2024|80
MicroSegNet: A deep learning approach for prostate segmentation on micro-ultrasound images
|Computerized Medical Imaging and Graphics|2024|76